CardioExchange Archive

September 5th, 2014

Perspectives on PARADIGM-HF

CardioExchange Editors, Staff

The Editors present a distillation of reader comments on a popular post.

---

August 30th, 2014

Will There Be a PARADIGM Shift in Treatment of Heart Failure?

John McMurray, MbChB MD and Milton Packer, MD

John J.V. McMurray and Milton Packer, the two lead authors of the PARADIGM-HF trial, discuss the randomized comparison of angiotensin–neprilysin inhibition with the ACE inhibitor enalapril.

---

March 31st, 2014

Novartis Trial Was Stopped Early Because of a Significant Drop in Cardiovascular Mortality

Larry Husten, PHD

The largest-ever trial in heart failure was stopped early because of a highly statistically significant reduction in cardiovascular mortality, according to one of the trial’s two primary investigators. Earlier today I reported that the PARADIGM-HF trial testing LCZ696, a novel, first-in-class Angiotensin Receptor Neprilysin Inhibitor (ARNI), had been stopped early because the trial had demonstrated a significant reduction in the combined […]

---

March 31st, 2014

Early Success for Novel Novartis Heart Failure Drug

Larry Husten, PHD

A large clinical trial testing a novel compound from Novartis for chronic heart failure has been stopped early for efficacy. In a press release Novartis said the Data Monitoring Committee had recommended early closure of the PARADIGM-HF trial because the trial had demonstrated a significant reduction in the combined primary endpoint of cardiovascular death and heart failure hospitalization. PARADIGM-HF randomized patients with heart failure […]

---